Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28716150 | 0.80 | KAT2B (0.30) | — | |
| SCHEMBL3845246 | 0.77 | CCNE1 (0.31) | — | |
| SCHEMBL25261082 | 0.77 | MAPT (0.31) | — | |
| SCHEMBL15921564 | 0.77 | CCNE1 (0.34) | — | |
| SCHEMBL31055871 | 0.76 | — | — | |
| SCHEMBL658838 | 0.69 | PRMT6 (0.31) | — | |
| SCHEMBL825772 | 0.69 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL42407 | 0.68 | FBP1 (0.43) | NOS1 | |
| SCHEMBL578124 | 0.68 | NOS1 (0.34) | NOS1 | |
| SCHEMBL18626716 | 0.67 | ALDH1A1 (0.40) | NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606562-B2 | Pyridopyrimidines derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-04-21 | — | — | US | disclosed |
| US-12534455-B2 | Phthalazine derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-01-27 | — | — | US | disclosed |
| US-12509479-B2 | P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2025-12-30 | — | — | US | disclosed |
| US-20250270190-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-08-28 | — | — | US | disclosed |
| EP-4549438-A1 | FIVE-MEMBERED AND SIX-MEMBERED NITROGEN-CONTAINING COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | Hangzhou Synrx Therapeutics Biomedical Technology Co., Ltd. (CN) | 2025-05-07 | — | — | EP | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4251617-B1 | (AZA)QUINOLINE 4-AMINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2025-03-12 | — | — | EP | disclosed |
| EP-4251273-B1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2025-03-12 | — | — | EP | disclosed |
| CN-119585250-A | KIT inhibitors | 蓝图药品公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-101983384-A | Prolyl hydroxylase inhibitors | SMITHKLINE BEECHAM CORP | 2011-03-02 | — | — | CN | disclosed |
| WO-2011017389-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| WO-2010118078-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| EP-2227770-A2 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2125801-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | Eisai R&D Management Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009073497-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2008095943-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534455-B2 | Phthalazine derivatives as P2X3 inhibitors | P2RX3, P2RX5, P2RX7 | NOS1 4262/4885 |
| US-12606562-B2 | Pyridopyrimidines derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX2 | NOS1 2763/4885 |
| US-20250270190-A1 | KIT INHIBITORS | KIT, ABL1, APC | NOS1 2109/4885 |
| US-12509479-B2 | P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof | P2RX3, P2RX6, P2RX2 | NOS1 4230/4885 |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | NOS1 287/4885 |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | NOS1 3504/4885 |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPKAPK5, MAPK13 | NOS1 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.